SCD5

Across TCGA pan-cancer cohorts, SCD5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SCD5 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SCD5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SCD5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where SCD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.784	0.340	<.001	34	view →
PDAC	OS	Median	All	0.377	0.650	<.001	28	view →
CCRCC	DFS	Quartile	II,III,IV	0.861	0.426	.005	15	view →
OV	DFS	Tertile	All	0.619	1.000	.034	8	view →
LUAD	DFS	Median	III,IV	0.867	0.614	.020	6	view →
GBM	OS	Median	All	0.618	0.892	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SCD5–HNSC (DFS)

Open the HNSC breakdown →